BioBridge Global Introduces BBG Advanced Therapies: New Subsidiary to Support the Development of Cell and Gene Therapies

Advanced Therapies Testing

BBG_BBGAT_HORIZ_4C-e1731966645877.png

A full range of RUO and cGMP qualified assays are available to support the Advanced Therapies industry. 

The team partners with clients to develop custom assays or tech-transferred assays to demonstrate the safety, purity and potency of advanced therapies. 

Custom platforms are available for development, qualification and validation of RUO and cGMP assays. 

A variety of assays are performed to verify the advanced therapies product is safe, and no contamination or safety issues are present for the recipient.

  • Rapid Endotoxin
  • Sterility with ID
  • Bioburden
  • Mycoplasma by PCR
  • Viral Marker Testing

A comprehensive range of analytical testing services to characterize advanced therapies products are available.

  • Cell count & viability
  • Flow cytometry 
  • Automated ELISA
  • Total protein concentration
  • CD flow markers for characterization of leukopaks

Development of custom potency assays or tech transfer of client-developed assays is available. Potency determination is necessary for regulatory submission and release of advanced therapies products. 

Qualification
Test Method Suitability Study can be required to ensure that the client sample is qualified and has no impact on assay performance.

Quality

The collaboratively integrated process with our quality team facilitates new testing and new product introduction. Customizable quality processes include phase appropriate and risk-based testing solutions assuring the safety, purity, identification and potency of cell-based products.

Commitment to Quality

Quality has been a guiding principle within BioBridge Global for more than 50 years.

Contact Us
For additional information about our products and services.
Certifications
View list of U.S. and international accreditations, certifications and registrations.
Search
Close this search box.